During fasting, mammals maintain normal glucose homeostasis by stimulating hepatic gluconeogenesis 1 . Elevations in circulating glucagon and epinephrine, two hormones that activate hepatic gluconeogenesis, trigger the cAMP-mediated phosphorylation of cAMP response element-binding protein (Creb) and dephosphorylation of the Creb-regulated transcription coactivator-2 (Crtc2)-two key transcriptional regulators of this process 2 . Although the underlying mechanism is unclear, hepatic gluconeogenesis is also regulated by the circadian clock, which coordinates glucose metabolism with changes in the external environment [3] [4] [5] [6] . Circadian control of gene expression is achieved by two transcriptional activators, Clock and Bmal1, which stimulate cryptochrome (Cry1 and Cry2) and Period (Per1, Per2 and Per3) repressors that feed back on Clock-Bmal1 activity. Here we show that Creb activity during fasting is modulated by Cry1 and Cry2, which are rhythmically expressed in the liver. Cry1 expression was elevated during the night-day transition, when it reduced fasting gluconeogenic gene expression by blocking glucagonmediated increases in intracellular cAMP concentrations and in the protein kinase A-mediated phosphorylation of Creb. In biochemical reconstitution studies, we found that Cry1 inhibited accumulation of cAMP in response to G proteincoupled receptor (GPCR) activation but not to forskolin, a direct activator of adenyl cyclase. Cry proteins seemed to modulate GPCR activity directly through interaction with G s a. As hepatic overexpression of Cry1 lowered blood glucose concentrations and improved insulin sensitivity in insulinresistant db/db mice, our results suggest that compounds that enhance cryptochrome activity may provide therapeutic benefit to individuals with type 2 diabetes.
We used an adenovirally encoded reporter, in which a cAMP response element (CRE) drives the expression of luciferase (CRE-luc), to evaluate the rhythmicity of hepatic Creb activity under fasting conditions 7 . To control for potential variations in pancreatic glucagon secretion among the different mice in our experimental population, we examined effects of intraperitoneal (i.p.) glucagon administration at different times of the day. I.p. glucagon administration increased the adenoviral CRE-luc reporter activity 40-fold better in mice fasted at Zeitgeber time 10-13 (ZT10-13, the day-to-night transition) than at ZT22-1, corresponding to the night-to-day transition ( Fig. 1a and Supplementary Fig. 1 ). Consistent with a rhythmic oscillation in Creb activity, glucagon re-injection to the same mice fasted at ZT6-9, near the day-to-night transition, caused a robust induction in hepatic CRE-luc reporter activity ( Supplementary Fig. 1) . These results suggest that the amplitude of hepatic Creb activation by fasting is gated in a circadian fashion.
On the basis of the changes in fasting CRE-luc reporter activity, we hypothesized that the circadian clock modulates the Creb-and Crtc2mediated effects on the gluconeogenic gene expression program. Supporting this idea, glucagon administration increased the gene expression of two key gluconeogenic factors (glucose-6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase-1 (Pck1)) to a greater extent in mice fasted at ZT10-13 ( Fig. 1b) . Consistently, i.p. glucagon administration increased hepatic Creb phosphorylation and Crtc2 dephosphorylation robustly in ZT10-13 fasted mice, but the increase was smaller in in ZT22-1 fasted mice ( Fig. 1c) . Together, these results indicate that the clock modulates fasting gluconeogenesis in part by regulating Creb and Crtc2 activities, as indicated by changes in their phosphorylation statuses. These observations are consistent with recent reports showing that the phosphorylation of Creb is rhythmic in vivo 8 .
Owing to the rhythmic Creb phosphorylation, we considered that the liver clock may exert global effects on the expression of cAMPinducible genes. In line with this idea, we identified 194 Creb targets among a set of 652 clock-controlled genes (CCGs) in published microarray databases of mouse liver [9] [10] [11] . To examine the relationship between Creb signaling and clock regulation, we plotted the distribution of the Creb-targeted CCGs according to the circadian timepoints of their peak expression. We found that not only the absolute number of Creb-targeted CCGs but also the ratio (versus the numbers of CCGs at the given circadian timepoints) showed a clear correlation at circadian time 22 (CT22) ( Supplementary Fig. 2 ) with the reduced levels of phosphorylated Creb that we observed at ZT22-1 (Fig. 1c) .
These rhythmic patterns generally coincided with the trough phase of Per2 ( Supplementary Fig. 2 ), a clock gene whose temporal expression reflects the endogenous clock activities, suggesting a common inhibitory mechanism between the Creb signaling and clock regulation at CT22.
We then evaluated the extent to which the rhythmic regulation of Creb activity is cell autonomous. Exposure to vasoactive intestinal peptide (VIP), a GPCR ligand, increased CRE-luc activity in mouse adult fibroblasts harboring the receptor Vipr2 (ref. 12) ( Fig. 2) . After synchronizing the cells by serum shock, we exposed them to VIP at specific times and found CRE-luc reporter activation that showed a rhythmic pattern, with peak (24 and 48 h) and trough (36-39 h) activities coinciding with those for a Per2 promoter-driven luciferase (Per2-luc) reporter ( Fig. 2a) . These results show the regulation of Creb pathway induction by a cell-autonomous circadian clock and are reminiscent of the circadian gating seen in the light signaling induction of a Per2::luc knockin reporter in mouse fibroblasts containing melanopsin (a light sensor GPCR) 13 .
Because CRE-luc activity in liver and in synchronized fibroblasts is lowest when Per-Cry activity is highest (ZT22), we tested the potential role of Crys in regulating Creb signaling. Overexpression of Cry1 or Cry2 in mouse fibroblasts ectopically expressingVipr2 and CREluc (designated Vipr2-CRE-luc cells) or HEK293T cells attenuated CRE-luc activity in cells exposed to VIP ( Fig. 2b-d) , whereas overexpression of Per1 did not show a significant effect (Fig. 2c) . The repression was dose dependent (Fig. 2d) . Consistent with the absence of E-boxes, known to be inhibited by Crys through Clock-Bmal1, within the CRE-luc reporter, Clock-Bmal1 did not activate CRE-luc expression, suggesting that the inhibitory effect of Crys on CRE-luc reporter is irrelevant to Clock-Bmal1-mediated transcriptional regulation ( Supplementary Fig. 3 ) 10 . Furthermore, Cry1 or Cry2 overexpression reduced the effects of urocortin-3, another GPCR ligand, on CRE-luc activity in cells expressing its receptor corticotropinreleasing factor receptor-2β (ref. 14) ( Supplementary Fig. 4 ). Thus, these data indicate that Crys may exert more general effects on GPCRmediated increases in Creb-and Crtc2-dependent transcription. Figure 1 Hepatic Creb-Crtc2 activity is modulated by the circadian clock. (a) Left, CRE-luc reporter activity in mice fasted for 3 h followed by i.p. glucagon administration. The relative effect of fasting at ZT10-13 (ZT13) and ZT22-1 (ZT1) is indicated. Right, bar graph showing CRE-luc activity from hepatic lysates normalized to β-galactosidase activity from co-infected Ad-RSV-β-gal adenovirus. *P < 0.01, n = 5. (b) Quantitative PCR analysis of gluconeogenic gene expression in mice fasted at ZT10-13 or ZT22-1 and then injected i.p. with glucagon (Glu). *P < 0.01, n = 5. (c) Immunoblot of Creb and Crtc2 proteins in liver extracts from mice fasted ZT10-13 (ZT13) or ZT22-1 (ZT1) followed by i.p. injection with glucagon. The relative effects ZT13 and ZT1 fasting on hepatic amounts of phospho-Crtc2 (p-Crtc2) and phospho-Creb (Ser133; p-Creb) are also shown. Dephosphorylated Crtc2 (active) runs faster than the p-Crtc2 (inactive) in ZT13 fasting mice. The loading control is heat-shock protein 90 (Hsp90). Data represent means ± s.e.m. 
l e t t e r s
Given the inhibitory effects of Cry proteins on multiple GPCR signaling in fibroblasts and HEK293T cells, it may also modulate the effects of glucagon on liver gene expression through the glucagon receptor, another GPCR. Supporting this notion, hepatic expression of adenovirally encoded Cry1 (Ad-Cry1) reduced glucagon-induced CRE-luc activity in liver of fasted mice at ZT10-13, when endogenous Cry1 expression is low (Fig. 3a) . Moreover, Ad-Cry1 also downregulated gluconeogenic gene expression (G6pc and Pck1) in fasted mice given glucagon i.p. (Fig. 3b) . Consequently, Ad-Cry1-expressing mice showed lower circulating blood glucose concentrations compared to Ad-GFP-expressing controls (Fig. 3c) .
We tested whether depletion of Cry, either by targeted disruption of the Cry1 and Cry2 genes 15 or by RNAi-mediated knockdown in the liver in vivo, was sufficient to increase Creb activity. By contrast with the circadian oscillation of hepatic CRE-luc induction in wildtype mice, glucagon-stimulated CRE-luc activity was constitutively elevated in Cry1 −/− ;Cry2 −/− mice (Supplementary Fig. 5) . Similarly, RNAi-mediated depletion of hepatic Cry1 and Cry2 increased glucagon-stimulated CRE-luc activity at ZT1 relative to control mice expressing nonspecific shRNA (USi) (Fig. 3d) . As a result, hepatic mRNA levels for gluconeogenic genes (G6pc and Pck1) were higher in mice with knocked down Cry1 and Cry2 expression compared to controls ( Fig. 3e) . Circulating glucose concentrations were elevated after Cry1 and Cry2 depletion (Supplementary Fig. 6 ), suggesting that circadian changes in hepatic Cry expression are sufficient to modulate the gluconeogenic genetic program, in part through their inhibitory effects on the Creb-Crtc2 pathway. Indeed, knockdown of Cry1 and Cry2 also increased glucose production in primary hepatocytes after exposure to glucagon, indicating that Cry effects on hepatic glucose metabolism are probably cell autonomous (Fig. 3f) .
We also wondered whether Cry would similarly modulate circulating glucose concentrations in the setting of insulin resistance. Supporting this idea, adenoviral expression of Cry1 reduced fasting blood glucose concentrations and improved whole-body insulin sensitivity in insulin-resistant db/db mice, as measured by glucose tolerance testing (Fig. 3g) . Pointing to a functional effect on hepatic gluconeogenesis, Cry1 overexpression also lowered glucose excursions in pyruvate tolerance-testing studies (Fig. 3h) .
Given the rhythmic changes in hepatic Creb phosphorylation and that glucagon mediates its effects in the liver by increasing intracellular cAMP abundance and thus activating Creb, we suspected that during fasting Cry1 may disrupt the effects of glucagon on adenyl cyclase activation. Supporting this idea, i.p. administration of glucagon increased hepatic cAMP concentrations at ZT10-13, when Cry1 expression is low, and to a much lesser extent, at ZT22-1 when Cry1 levels are elevated (Fig. 4a) . Furthermore, we consistently found that Ad-Cry1 expression markedly reduced hepatic cAMP concentrations in ZT10-13 fasted mice exposed to glucagon (Fig. 4b) . Indeed, the amount of phosphorylated Creb was lower in livers of fasted Ad-Cry1 mice compared to Ad-GFP control mice (Fig. 4c) .
We evaluated the effects of Cry proteins on Creb-Crtc2 signaling in cultures of primary hepatocytes. Similar to its effects in liver in vivo, Ad-Cry1 also downregulated CRE-luc reporter activity, as well as gluconeogenic gene expression in cultured cells exposed to glucagon ( Supplementary Fig. 7a,b) . By contrast with its effect in cells exposed to glucagon, Ad-Cry1 did not reduce gluconeogenic gene expression or CRE-luc reporter activity in cells treated with forskolin, a direct activator of adenyl cyclase. Consistent with these results, Ad-Cry1 expression reduced cAMP accumulation in cells exposed to glucagon but not to forskolin (Fig. 4d) . In addition, RNAi-mediated knockdown of Cry1 and Cry2 increased cAMP content in primary hepatocytes exposed to glucagon but not to forskolin (Supplementary Fig. 7c ). Pointing to a more general effect of this repressor on GPCR signaling, Cry1 or Cry2 overexpression also reduced cAMP accumulation in response to VIP treatment in fibroblasts expressing Vipr2 (Supplementary Fig. 8 ). Together, these results indicate that Cry1 acts upstream of adenyl cyclase to regulate hepatic Creb activity during fasting. To evaluate further the mechanism by which Cry proteins inhibit cAMP signaling, we performed in vitro reconstitution assays. Addition of isoproterenol to plasma membranes from HEK293T cells, which express β-adrenergic receptors, increased cAMP accumulation in vitro (Fig. 4e,f) . Co-incubation of plasma membrane fractions with cytoplasmic extracts from transfected HEK293T cells expressing Cry1 potently inhibited cAMP increases in response to isoproterenol relative to control (GFP) extracts (Fig. 4e) . We considered that Cry1 could disrupt cAMP accumulation either directly by binding to relevant signaling components or indirectly by stimulating the expression of an intracellular inhibitor. Supporting the former hypothesis, immunodepletion of hemagglutinin (HA)-tagged Cry1 with HA-specific antiserum restored cAMP accumulation in response to isoproterenol, whereas control IgG had no effect (Fig. 4f) . Taken together, these results demonstrate that Cry1 inhibits activation of the Creb-Crtc2 pathway in liver by disrupting cAMP production in response to ligand-dependent activation of G s -coupled receptors.
Given the ability of Cry to disrupt GPCR-initiated, but not forskolinmediated, increases in cAMP production, Cry would be predicted to associate with either GPCRs or with the G s α subunit of heterotrimeric G protein. Although it did not interact detectably with the GPCR family member Vipr2, Cry associated with G s α in pull-down assays of membrane fractions from transfected HEK293T cells incubated with recombinant GST-Cry protein (Fig. 4g) . We also observed the Cry-G s α interaction in reciprocal coimmunoprecipitation assays of HEK293T cells and primary hepatocytes (Fig. 4h) . Together, these data show a role for extranuclear Cry in regulating cAMP production.
The circadian clock has been known to modulate hepatic gluconeogenesis for over 20 years, although the underlying mechanism has remained unclear. We found that the liver clock regulates the gluconeogenic genetic program through Cry-mediated inhibition of Creb activity during fasting. Historically regarded as a transcriptional repressor, Cry seemed to inhibit gluconeogenic gene expression primarily by blocking GPCR-mediated increases in cAMP and the subsequent phosphorylation of Creb (Fig. 4i) . These results are consistent with recent findings that hepatic Creb phosphorylation oscillates in a circadian fashion 8 . Similar to our observations in liver, cAMP concentrations have also been found to oscillate in the clock master organ, the suprachiasmatic nucleus, reaching a nadir when Cry expression is highest 16 . Future studies should provide further insight in to the detailed mechanism by which Cry modulates G s effects on cAMP in liver and other tissues.
MEtHoDs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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